Journal article
New studies of BCG: implications for tuberculosis vaccines
BCG has been given to over 3 billion people since the early part of the 20th century. Although the vaccine is effective, its use was implemented before clinical-trial design had reached its current sophistication, and before sensitive in-vitro techniques of assessing cellular immune responses were available. Recent studies and reinterpretation of previous trials have helped to clarify the true efficacy of BCG against both infection with and disease caused by Mycobacterium tuberculosis, while large cohort studies have provided an accurate side-effect profile in recipients with HIV infection.
Authors
Languages
- English
Journal
The Lancet Infectious Diseases
Volume
4
Type
Journal article
Categories
- Vaccines & delivery devices